Personalis ROE 2018-2026 | PSNL
Current and historical return on equity (ROE) values for Personalis (PSNL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Personalis ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-06-30 | $-0.11B | $0.23B | -46.85% |
| 2026-03-31 | $-0.10B | $0.22B | -43.74% |
| 2025-12-31 | $-0.08B | $0.21B | -39.52% |
| 2025-09-30 | $-0.07B | $0.19B | -38.34% |
| 2025-06-30 | $-0.09B | $0.19B | -47.40% |
| 2025-03-31 | $-0.08B | $0.17B | -48.77% |
| 2024-12-31 | $-0.08B | $0.15B | -53.73% |
| 2024-09-30 | $-0.09B | $0.13B | -69.57% |
| 2024-06-30 | $-0.08B | $0.13B | -63.94% |
| 2024-03-31 | $-0.09B | $0.14B | -64.47% |
| 2023-12-31 | $-0.11B | $0.16B | -67.08% |
| 2023-09-30 | $-0.11B | $0.19B | -61.16% |
| 2023-06-30 | $-0.11B | $0.21B | -53.01% |
| 2023-03-31 | $-0.11B | $0.23B | -49.62% |
| 2022-12-31 | $-0.11B | $0.25B | -44.66% |
| 2022-09-30 | $-0.10B | $0.28B | -36.96% |
| 2022-06-30 | $-0.09B | $0.30B | -31.68% |
| 2022-03-31 | $-0.08B | $0.32B | -25.69% |
| 2021-12-31 | $-0.07B | $0.33B | -19.67% |
| 2021-09-30 | $-0.06B | $0.30B | -19.22% |
| 2021-06-30 | $-0.05B | $0.27B | -18.42% |
| 2021-03-31 | $-0.04B | $0.21B | -20.95% |
| 2020-12-31 | $-0.04B | $0.15B | -27.75% |
| 2020-09-30 | $-0.04B | $0.13B | -27.83% |
| 2020-06-30 | $-0.03B | $0.10B | -31.22% |
| 2020-03-31 | $-0.03B | $0.11B | -26.73% |
| 2019-12-31 | $-0.03B | $0.08B | -31.04% |
| 2019-06-30 | $-0.02B | $0.03B | -54.70% |
| 2019-03-31 | $-0.02B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |